<DOC>
	<DOC>NCT01045109</DOC>
	<brief_summary>This clinical trial is aimed at measuring the effect of vitamin D3 supplementation on serum prostate-specific antigen (PSA) levels in patients diagnosed with early stage, low-grade, low-risk prostate cancer (Gleason score less than/equal to 6; PSA less than/equal to 10; clinical stage T1C or T2a), who elect to have their disease monitored through active surveillance for at least one year.</brief_summary>
	<brief_title>Vitamin D3 Supplementation in Participants Diagnosed With Early-Stage Prostate Cancer Who Decide to Undergo Active Surveillance Treatment Regimen.</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>lowgrade prostate cancer serum PSA less than/equal to 10 ng/ml Gleason score less than/equal to 6 referred from their treating physician with treatment plan of active surveillance for one year serum creatinine less than/equal to 2.0 mg/dL serum phosphate (measured as phosphorus)greater than 2.3 and less than 4.8 mg/dL serum calcium greater than 8.5 and less than 10.5 mg/dL concurrent malignancy, except nonmelanoma skin cancer history of sarcoidosis history of high dose (greater than 1,000 IU daily) vitamin D3 supplementation history of hypercalcemia treatment with lithium medication</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>prostate</keyword>
	<keyword>cancer</keyword>
	<keyword>vitamin D3</keyword>
	<keyword>early stage</keyword>
	<keyword>active surveillance</keyword>
</DOC>